Study of side effects and response to anti-VEGF treatments
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at the side effects (complications) and how well people respond when they receive anti-VEGF cancer medicines. It may help doctors better manage treatment and understand who benefits most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and are willing to sign consent paperwork
- You are currently receiving an anti-VEGF-related cancer treatment
- Your anti-VEGF treatment can be only one medicine or a combination with other medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people with blood cancers do after they receive CAR-T therapy, radiation therapy, and/or bispecific therapy. It may help doctors understand which treatment combinations work best and what side effects to expect.
This study uses special cells grown in a lab to understand why some cancer treatments cause side effects. It may help researchers find ways to predict and prevent these side effects in the future.
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
This study looks at how your body responds to immunotherapy and how to manage side effects. It aims to separate the treatment's benefits from its unwanted reactions.
This trial aims to improve how doctors spot and track side effects from immunotherapy. If you are on or have had immunotherapy, your experience can help build a better system for monitoring these treatments.
This study looks at side effects from immunotherapy in people with solid or blood cancers. It may help doctors better manage these side effects in the future.
Hear when a new Hematopoietic and Lymphoid Cell Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.